2013 saw the Swedish Biotech Industry raising a significantly smaller venture financing amount than in the year before (USD 27m compared to USD 127m in 2012). During the same period the number of companies achieving an IPO exit doubled. The number of biotech products in Phase I of development remained stable compared to last year, … Continue reading Swedish Life Sciences Trend Analysis 2014
Category: Life Sciences Reports
This area includes the yearly life sciences and Biotech reports with statistics retrieved from Biotechgate.
French Life Sciences Trend Analysis 2014
The number of Biotech (Therapeutics and Diagnostics) companies founded in France in 2013 was double that of the previous year. At the same time, the 2013 total venture financing value was increased for a third consecutive year, reaching USD 197m; 30% higher than in 2012 (USD 151m). Click here to download French Life Sciences Trend … Continue reading French Life Sciences Trend Analysis 2014
German Life Sciences Trend Analysis 2014
In 2013, the total financing value raised by private, Biotech companies in Germany was reduced by 31% compared to last year’s figure (USD 210m from what was USD 305m in 2012). However, this summer’s snapshot of the German biotech industry, suggests that the therapeutics pipeline is revitalized, since the number of products in earlier stages … Continue reading German Life Sciences Trend Analysis 2014
Dutch Life Sciences Trend Analysis 2014
With a strong finish in the second half of 2013, the Dutch, private biotechnology companies closed the year having amassed a total of USD 158m in venture financing. The strongest therapeutic areas, as represented by the biotech product pipeline (Therapeutics and Diagnostics), are those of Oncology (53 products in development), Infectious Diseases (36 products) and … Continue reading Dutch Life Sciences Trend Analysis 2014
Swiss Life Sciences Trend Analysis 2014
While the number of Swiss Biotech companies in 2013 remained close to its 2012 levels, the total financing value amassed within the sector more than doubled compared to last year’s figure, reaching USD 325m (112% increase). Click here to download Swiss Life Sciences Trend Analysis 2014 – 14 pages Looking for your next Biotech or … Continue reading Swiss Life Sciences Trend Analysis 2014
Spanish Life Sciences Trend Analysis 2014
Biotech financing activity in Spain in 2013 was slower compared to 2012 (43% fewer financing rounds and no IPOs). Nevertheless, the total financing value raised by Biotechs increased by approximately 10% during the same period. Click here to download Spanish Life Sciences Trend Analysis 2014 – 14 pages Looking for your next Biotech or Medtech … Continue reading Spanish Life Sciences Trend Analysis 2014
South Korean Life Sciences Trend Analysis 2013
Financing value in South Korean Biotech (Therapeutics & Diagnostics) in 2013 more than doubled that of 2012, reaching a historical high value of 21.7 billion KRW (23.7 million USD). Click here to download South Korean Life Sciences Trend Analysis 2013 – 12 pages
German Life Sciences Trend Analysis 2013
In the past year, the German biotech sector experienced a modest growth with a 17% increase in Biotech Therapeutics companies and a 48% increase in total financing value. Click here to download German Life Sciences Trend Analysis 2013 – 12 pages
UK Life Sciences Trend Analysis 2013
From 2007 to 2012, the market witnessed a steady increase of biotech financing value in the UK. Moreover, the year 2012 almost doubled the financing value of 2011. Click here to download UK Life Sciences Trend Analysis 2013 – 12 pages
French Life Sciences Trend Analysis 2013
2012 saw a six-fold increase in total financing value to USD 150 M in unison with a substantial increase in total number of Biotech companies. Click here to download French Life Sciences Trend Analysis 2013 – 12 pages